eISSN 2508-3589
pISSN 2508-1926

Fig. 3.

Download original image
Fig. 3. The mean change in (A) BCVA and (B) central macular thickness (CMT) from baseline to 12 months for all patients with treat-and-extend regimen using aflibercept for exudative age-related macular degeneration. BCVA = best-corrected visual acuity; logMAR = logarithm of the minimum angle of resolution. *p < 0.05.
J Retin 2021;6:99-109 https://doi.org/10.21561/jor.2021.6.2.99
© 2021 J Retin